| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9572803 | TEVA BRANDED PHARM | Abuse resistant drug formulation |
Sep, 2027
(3 years from now) | |
| US9216176 | TEVA BRANDED PHARM | Abuse resistant drug formulation |
Sep, 2027
(3 years from now) | |
| US8445018 | TEVA BRANDED PHARM | Abuse resistant drug formulation |
Jul, 2029
(5 years from now) | |
Vantrela Er is owned by Teva Branded Pharm.
Vantrela Er contains Hydrocodone Bitartrate.
Vantrela Er has a total of 3 drug patents out of which 0 drug patents have expired.
Vantrela Er was authorised for market use on 17 January, 2017.
Vantrela Er is available in tablet, extended release;oral dosage forms.
The generics of Vantrela Er are possible to be released after 31 July, 2029.
Drugs and Companies using HYDROCODONE BITARTRATE ingredient
Market Authorisation Date: 17 January, 2017
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
VANTRELA ER family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic